Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:31 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: | NSE:

Ajooni Biotech Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹3.20Overvalued by 22.14%vs CMP ₹4.11

P/E (14.4) × ROE (5.2%) × BV (₹5.29) × DY (2.00%)

₹4.32Fairly Valued by 5.11%vs CMP ₹4.11
MoS: +4.9% (Thin)Confidence: 48/100 (Moderate)Models: 5 Under, 4 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹4.5523%Under (+10.7%)
Graham NumberEarnings₹5.8817%Under (+43.1%)
Earnings PowerEarnings₹0.4511%Over (-89.1%)
DCFCash Flow₹6.6011%Under (+60.6%)
Net Asset ValueAssets₹5.177%Under (+25.8%)
EV/EBITDAEnterprise₹2.969%Over (-28%)
Earnings YieldEarnings₹2.907%Over (-29.4%)
ROCE CapitalReturns₹2.947%Over (-28.5%)
Revenue MultipleRevenue₹6.686%Under (+62.5%)
Consensus (9 models)₹4.32100%Fairly Valued
Key Drivers: EPS CAGR 42.1% lifts DCF — verify sustainability. | Wide model spread (₹0–₹7) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 42.1%

*Investments are subject to market risks

Investment Snapshot

56
Ajooni Biotech Ltd scores 56/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health53/100 · Moderate
ROCE 6.9% WeakROE 5.2% WeakD/E 0.43 ModerateInterest Coverage 0.0x RiskyProfitable 4/5 years Consistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 26.9% Stable
Earnings Quality40/100 · Moderate
OPM stable around 3% SteadyWorking capital: 160 days Capital intensive
Quarterly Momentum90/100 · Strong
Revenue (4Q): +44% YoY AcceleratingProfit (4Q): +79% YoY Strong
Industry Rank45/100 · Moderate
P/E 14.4 vs industry 24.2 Cheaper than peersROCE 6.9% vs industry 15.1% Below peersROE 5.2% vs industry 13.4% Below peers3Y sales CAGR: 16% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:31 am

Market Cap 70.8 Cr.
Current Price 4.11
Intrinsic Value₹4.32
High / Low 6.60/3.55
Stock P/E14.4
Book Value 5.29
Dividend Yield0.00 %
ROCE6.91 %
ROE5.15 %
Face Value 2.00
PEG Ratio0.34

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Ajooni Biotech Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Ajooni Biotech Ltd 70.8 Cr. 4.11 6.60/3.5514.4 5.290.00 %6.91 %5.15 % 2.00
Godrej Agrovet Ltd 10,984 Cr. 571 876/50623.8 94.11.93 %16.6 %17.7 % 10.0
Avanti Feeds Ltd 16,671 Cr. 1,224 1,489/58226.4 2210.74 %24.0 %19.5 % 1.00
Narmada Agrobase Ltd 123 Cr. 32.5 36.0/14.632.1 15.30.00 %13.0 %11.2 % 10.0
Industry Average9,259.33 Cr457.9024.1883.920.67%15.13%13.39%5.75

All Competitor Stocks of Ajooni Biotech Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 10.6341.2621.0019.4820.0519.5825.6625.7234.0329.2731.2731.7458.75
Expenses 10.1540.3220.3418.8520.7017.9924.7024.9533.1028.2630.5630.2455.72
Operating Profit 0.480.940.660.63-0.651.590.960.770.931.010.711.503.03
OPM % 4.52%2.28%3.14%3.23%-3.24%8.12%3.74%2.99%2.73%3.45%2.27%4.73%5.16%
Other Income 0.020.260.070.291.570.260.040.310.391.340.650.150.32
Interest 0.130.120.130.190.120.110.150.060.070.060.080.170.18
Depreciation 0.260.240.210.210.210.240.220.230.240.380.250.250.81
Profit before tax 0.110.840.390.520.591.500.630.791.011.911.031.232.36
Tax % 0.00%35.71%-2.56%23.08%23.73%38.67%25.40%22.78%27.72%19.37%24.27%24.39%30.08%
Net Profit 0.110.540.400.400.440.910.470.620.731.540.780.931.65
EPS in Rs 0.010.030.020.020.030.050.030.040.040.090.050.050.10

Last Updated: February 6, 2026, 10:47 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 18, 2026, 1:16 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 17132942404051747480115151
Expenses 17132841393949717278111145
Operating Profit 0001111233246
OPM % 2%2%2%2%2%2%3%3%4%4%3%3%4%
Other Income 0000000000222
Interest 0000000110100
Depreciation 0000000111112
Profit before tax 0000000012347
Tax % 0%27%29%28%20%15%29%26%28%28%28%22%
Net Profit 0000000011235
EPS in Rs 0.020.120.180.360.030.030.020.020.050.060.120.200.29
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%100.00%50.00%
Change in YoY Net Profit Growth (%)0.00%100.00%-50.00%

Ajooni Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:32%
5 Years:23%
3 Years:16%
TTM:42%
Compounded Profit Growth
10 Years:47%
5 Years:56%
3 Years:47%
TTM:65%
Stock Price CAGR
10 Years:%
5 Years:-7%
3 Years:-19%
1 Year:-49%
Return on Equity
10 Years:5%
5 Years:5%
3 Years:5%
Last Year:5%

Last Updated: September 4, 2025, 9:40 pm

Balance Sheet

Last Updated: January 7, 2026, 3:17 pm

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 0.240.240.240.33668101018183434
Reserves 00015676624255455
Borrowings 0011555755229
Other Liabilities 011114126712355
Total Liabilities 022131918232829594895104
Fixed Assets 0001112566101111
CWIP 00000000001011
Investments 0006643114233
Other Assets 0126121318222248348078
Total Assets 022131918232829594895104

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 0-1-3-3-5-414-623-18
Cash from Investing Activity + -0-0-2-010-3-2-168-17
Cash from Financing Activity + 0158-132-222-425
Net Cash Flow 0-005-5-10-0027-10
Free Cash Flow -0-1-3-3-5-6-22-817-19
CFO/OP 169%-257%-427%-284%-706%-353%71%125%-185%1,047%-458%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow0.000.00-1.000.00-4.00-4.00-4.00-5.00-2.00-2.000.002.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 58403317254411598681015952
Inventory Days 1412214631951344634398090
Days Payable 10066277991220463956813
Cash Conversion Cycle 99-42013584129986383131129
Working Capital Days 9659-29-184105775894132160
ROCE %28%18%37%10%4%4%5%9%6%8%7%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 36.39%30.28%27.46%26.44%26.44%26.89%26.89%26.89%26.89%26.89%26.89%26.89%
FIIs 0.01%0.00%0.00%0.00%0.00%0.00%0.29%0.18%0.00%0.00%0.00%0.00%
Public 63.59%69.72%72.53%73.56%73.56%73.11%72.82%72.92%73.11%73.11%73.11%73.11%
No. of Shareholders 21,18721,54822,95030,93341,05351,22463,90664,10263,96863,30564,30562,699

Shareholding Pattern Chart

No. of Shareholders

Ajooni Biotech Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.0010.0010.00
Basic EPS (Rs.) 0.200.251.941.050.37
Diluted EPS (Rs.) 0.200.251.941.050.37
Cash EPS (Rs.) 0.250.340.242.160.95
Book Value[Excl.RevalReserv]/Share (Rs.) 5.114.874.7616.3715.64
Book Value[Incl.RevalReserv]/Share (Rs.) 5.114.874.7616.3715.64
Revenue From Operations / Share (Rs.) 6.669.148.5074.0051.01
PBDIT / Share (Rs.) 0.330.500.343.111.66
PBIT / Share (Rs.) 0.270.400.232.001.09
PBT / Share (Rs.) 0.250.340.171.460.50
Net Profit / Share (Rs.) 0.190.240.121.050.37
PBDIT Margin (%) 5.015.524.104.203.26
PBIT Margin (%) 4.064.432.752.702.13
PBT Margin (%) 3.773.732.111.970.98
Net Profit Margin (%) 2.942.691.501.410.73
Return on Networth / Equity (%) 3.825.062.696.402.38
Return on Capital Employeed (%) 5.167.984.7210.556.20
Return On Assets (%) 3.544.541.913.611.33
Long Term Debt / Equity (X) 0.020.030.040.150.12
Total Debt / Equity (X) 0.060.050.120.320.43
Asset Turnover Ratio (%) 1.611.511.702.602.00
Current Ratio (X) 12.8610.742.282.182.05
Quick Ratio (X) 7.895.631.821.601.53
Inventory Turnover Ratio (X) 5.836.2510.2711.3510.01
Interest Coverage Ratio (X) 17.227.956.405.762.85
Interest Coverage Ratio (Post Tax) (X) 11.094.883.352.941.64
Enterprise Value (Cr.) 95.0653.4339.4872.6336.96
EV / Net Operating Revenue (X) 0.820.660.520.980.72
EV / EBITDA (X) 16.5112.0712.9023.3422.19
MarketCap / Net Operating Revenue (X) 0.840.640.460.900.59
Price / BV (X) 1.101.210.834.111.94
Price / Net Operating Revenue (X) 0.840.640.460.900.59
EarningsYield 0.030.040.030.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Ajooni Biotech Ltd. is a Public Limited Listed company incorporated on 17/02/2010 and has its registered office in the State of Punjab, India. Company's Corporate Identification Number(CIN) is L85190PB2010PLC040162 and registration number is 040162. Currently company belongs to the Industry of Animal/Shrimp Feed. Company's Total Operating Revenue is Rs. 114.69 Cr. and Equity Capital is Rs. 34.45 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Animal/Shrimp FeedD-118, Industrial Area, Phase - VII, Mohali Punjab 160055Contact not found
Management
NamePosition Held
Mr. Jasjot SinghManaging Director & CFO
Mr. Gursimran SinghWhole Time Director
Mr. Partek SinghDirector
Mr. Ramandeep SinghIndependent Director
Mr. Imteshwar SinghIndependent Director
Ms. Simmi ChabbraIndependent Director
Mr. Ishtneet BhatiaIndependent Director

FAQ

What is the intrinsic value of Ajooni Biotech Ltd and is it undervalued?

As of 18 April 2026, Ajooni Biotech Ltd's intrinsic value is ₹4.32, which is 5.11% higher than the current market price of ₹4.11, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (5.15 %), book value (₹5.29), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Ajooni Biotech Ltd?

Ajooni Biotech Ltd is trading at ₹4.11 as of 18 April 2026, with a FY2026-2027 high of ₹6.60 and low of ₹3.55. The stock is currently near its 52-week low. Market cap stands at ₹70.8 Cr..

How does Ajooni Biotech Ltd's P/E ratio compare to its industry?

Ajooni Biotech Ltd has a P/E ratio of 14.4, which is below the industry average of 24.18. This is broadly in line with or below the industry average.

Is Ajooni Biotech Ltd financially healthy?

Key indicators for Ajooni Biotech Ltd: ROCE of 6.91 % is on the lower side compared to the industry average of 15.13%; ROE of 5.15 % is below ideal levels (industry average: 13.39%). Dividend yield is 0.00 %.

Is Ajooni Biotech Ltd profitable and how is the profit trend?

Ajooni Biotech Ltd reported a net profit of ₹3 Cr in Mar 2025 on revenue of ₹115 Cr. Compared to ₹1 Cr in Mar 2022, the net profit shows an improving trend.

Does Ajooni Biotech Ltd pay dividends?

Ajooni Biotech Ltd has a dividend yield of 0.00 % at the current price of ₹4.11. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Ajooni Biotech Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports